TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9755264
Drug: DTaP vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTaP vaccine (acellular pertussis component DTP vaccine)
Study: 9755264
Drug: DTP vaccine
Normalized name: DTP Vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTP vaccine (whole cell pertussis component DTP vaccine)
Study: 9755264
Drug: DT vaccine
Normalized name: Diphtheria Toxoid, Adsorbed/Tetanus Toxoid Intramuscular Suspension [DT VACCINE ADSORBED PEDIATRIC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: DT vaccine (diphtheria and tetanus toxoids vaccine)
Study: 30940217
Drug: Plant extract
Normalized name: Plant extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant extract supplement (Aloe gel, grape juice, Polygonum cuspidatum)
Study: 30047573
Drug: Hydroxychloroquine (HCQ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxychloroquine (HCQ 200 mg)
Study: 30047573
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA 81 mg)
Study: 17239798
Drug: Oral anticoagulants
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulants (target INR range 2.0-3.0)
Study: 17239798
Drug: Aspirin (30-325
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (30-325 mg daily)
Study: 8305412
Drug: Lovastatin alone
Normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lovastatin alone or in combination with fish oil concentrate
Study: 31815643
Drug: 5 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 days of antibiotic prophylaxis
Study: 22006873
Drug: Elective left
Normalized name: hetastarch
DrugBank: Hydroxyethyl Starch (DB09106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elective left colectomy for colon cancer (CC)
Study: 17680654
Drug: PEG-IFN-alpha-2a and
Normalized name: PEG-IFN alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PEG-IFN-alpha-2a and ribavirin after 14-day dosing period
Study: 11510709
Drug: Dalteparin 2,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalteparin 2,500 iu, subcutaneously once daily for four or five days post-operatively
Study: 11510709
Drug: Saline (placebo),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (placebo), subcutaneously once daily for four or five days post-operatively
Study: 9300751
Drug: Postoperative low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative low dose radiotherapy (5 x 2 Gy; total: 10 Gy)
Study: 9300751
Drug: Postoperative medium
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative medium dose radiotherapy (5 x 3.5 Gy; total: 17.5 Gy)
Study: 28749095
Drug: Remifentanil concentration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil concentration 2 ng/mL
Study: 28749095
Drug: Remifentanil concentration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil concentration 6 ng/mL
Study: 24366103
Drug: Inosine (500-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inosine (500-mg capsules taken orally up to 2 capsules 3 times per day)
Study: 19112800
Drug: Fractional photothermolysis
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractional photothermolysis treatment
Study: 16650421
Drug: Single-dose methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single-dose methotrexate (MTX)
Study: 16650421
Drug: Multiple-dose methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Multiple-dose methotrexate (MTX)
Study: 12785439
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no extra treatment)
Study: 9174562
Drug: Fluoxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (20 mg daily) + Pindolol (7.5 mg daily)
Study: 10967371
Drug: Fluoxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (20 mg daily) + Placebo
Study: 17170650
Drug: Topical diclofenac
Normalized name: diclofenac Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical diclofenac sodium
Study: 29782196
Drug: Topical fluorometholone
Normalized name: Fluorometholone
DrugBank: Fluorometholone (DB00324)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical fluorometholone
Study: 21041914
Drug: Ritonavir-boosted atazanavir
Normalized name: atazanavir and ritonavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir-boosted atazanavir (ATV/RTV; 300/100 mg once daily)
Study: 21041914
Drug: Unboosted atazanavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unboosted atazanavir (ATV; 400 mg once daily)
Study: 16808310
Drug: rHuEPO therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHuEPO therapy (5000 IU 2 times per week s.c. for 4 months)
Study: 16808310
Drug: Clinical observation
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical observation (no rHuEPO therapy)
Study: 1516500
Drug: Morning NPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning NPH insulin
Study: 23426412
Drug: Retapamulin 1%
Normalized name: RETAPAMULIN 1% OINT,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retapamulin 1% applied twice daily for 5 days
Study: 23426412
Drug: Placebo ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo ointment applied twice daily for 5 days
Study: 19393841
Drug: 7-day buprenorphine
Normalized name: buprenorphine
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 7-day buprenorphine patches (5, 10, and 20 microg/h, maximum dosage of 20 microg/h)
Study: 19393841
Drug: Prolonged-release tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged-release tramadol tablets (75, 100, 150, and 200 mg, maximum dosage of 400 mg/d)
Study: 19393841
Drug: 7-day buprenorphine
Normalized name: buprenorphine
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 7-day buprenorphine patches
Study: 19393841
Drug: Prolonged-release tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged-release tramadol tablets
Study: 11430634
Drug: Budipine 10
Normalized name: budipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budipine 10 mg single dose
Study: 11430634
Drug: Budipine 10
Normalized name: budipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budipine 10 mg t.i.d for 10 days
Study: 11430634
Drug: Budipine 20
Normalized name: budipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budipine 20 mg single dose
Study: 11430634
Drug: Budipine 30
Normalized name: budipine 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budipine 30 mg single dose
Study: 7839462
Drug: Preoperative intra-arterial
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Preoperative intra-arterial mitomycin-C (10 mg/m2 in 500 ml normal saline over 6 hours)
Study: 3284340
Drug: norfloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: norfloxacin (400 mg every 12 hours)
Study: 3284340
Drug: cotrimoxazole (160/800
Approvals — FDA: no, EMA: no, PMDA: no
Description: cotrimoxazole (160/800 mg every 12 hours)
Study: 30578013
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of intravenous (IV) amoxicillin‐clavulanate TID
Study: 30578013
Drug: 50 mL
Normalized name: TPN Bag 250 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mL of IV 0.9% NaCl TID (placebo)
Study: 28925502
Drug: No-antibiotic regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-antibiotic regimen with supportive care (intravenous fluids, analgesia, and antipyretics as necessary)
Study: 28925502
Drug: 4-day course
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-day course of antibiotics with supportive care
Study: 28925502
Drug: No-antibiotic regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-antibiotic regimen with supportive care
Study: 21701333
Drug: Intradermal avotermin
Normalized name: avotermin
DrugBank: Avotermin (DB11955)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal avotermin (200 ng/100 μl/linear cm wound margin)
Study: 21701333
Drug: Intradermal avotermin
Normalized name: avotermin
DrugBank: Avotermin (DB11955)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal avotermin
Study: 19114324
Drug: Somatostatin bolus
Normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin bolus infusion before ERCP followed by continuous infusion for 12 hours
Study: 19114324
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no somatostatin treatment)
Study: 16490019
Drug: Sexual counseling
Normalized name: Zinc Gluconate 50 mg ORAL CAPSULE [Pegasus Male Sexual Enhancer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sexual counseling and PGE1-intracavernous injection (ICI) therapy (SC+)
Study: 16490019
Drug: Only PGE1-intracavernous
Normalized name: PGE1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Only PGE1-intracavernous injection (ICI) therapy (SC-)
Study: 14555866
Drug: Early treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early treatment with antidepressants (started within the first month after stroke)
Study: 14555866
Drug: Late treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late treatment with antidepressants (started after 1 month)
Study: 7868799
Drug: Radiotherapy (RT)
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiotherapy (RT) and Chemotherapy (CT)
Study: 7868799
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (RT and CT)
Study: 21296694
Drug: Speeda Vero
Approvals — FDA: no, EMA: no, PMDA: no
Description: Speeda Vero cell rabies vaccine (Group A)
Study: 21296694
Drug: Verorab Vero
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verorab Vero cell rabies vaccine (Group B)
Study: 18675569
Drug: Systemic alpha-lipoic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic alpha-lipoic acid (ALA) 400 mg
Study: 18675569
Drug: ALA (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALA (400 mg) plus vitamins
Study: 16893702
Drug: Implanted cardioverter
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implanted cardioverter defibrillator therapy
Study: 15254792
Drug: alpha-dihydroergocryptine (DEC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha-dihydroergocryptine (DEC) 101+/−39 mg
Study: 15254792
Drug: levodopa 369+/−51
Approvals — FDA: no, EMA: no, PMDA: no
Description: levodopa 369+/−51 mg
Study: 11766830
Drug: Subcutaneous GH
Normalized name: FUSION PROTEIN OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG- .BETA.)-(118-145)-PEPTIDE (1-28) WITH HUMAN SOMATOTROPIN (GROWTH HORMONE, GH) (29-219) AND TWO TANDEM COPIES OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG-.BETA.)-(118-145)- PEPTIDE (220-247
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous GH (2 IU daily) for a minimum of 12 weeks
Study: 9415571
Drug: 2-hour infusion
Normalized name: Interleukin-2/diptheria toxin fusion protein
DrugBank: Denileukin diftitox (DB00004)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2-hour infusion of OKT3
Study: 9415571
Drug: Intravenous bolus
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous bolus infusion of OKT3
Study: 8257887
Drug: Zidovudine 1500
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zidovudine 1500 mg/day
Study: 8257887
Drug: Zidovudine 500
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zidovudine 500 mg/day
Study: 8257887
Drug: Zidovudine early
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zidovudine early treatment
Study: 31398997
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of dry extract of ginger (5% active ingredient) three times per day for three months
Study: 25457929
Drug: Medication management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication management plus instructions in cognitive-behavioral therapy (CBT)
Study: 28412602
Drug: Medication management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication management plus full CBT
Study: 22955172
Drug: Lenalidomide (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide (single doses of 5-400 mg)
Study: 12435003
Drug: Various disinfecting
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Various disinfecting solutions
Study: 12435003
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no disinfecting solution)
Study: 9987734
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist (GnRHa) with hMG/hCG and DIPI
Study: 6853264
Drug: Misonidazole (MISO)
Normalized name: Metronidazole
DrugBank: Misonidazole (DB11716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Misonidazole (MISO) administered orally at a dose of 3.0g/m2 and intravesically at a dose of 1.0g
Study: 22260826
Drug: Immune-enhancing enteral
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immune-enhancing enteral solution (group II)
Study: 22260826
Drug: Standard enteral
Normalized name: Standard enteral formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard enteral solution (group III)
Study: 22260826
Drug: Parenteral solution
Normalized name: Triferic, 27.2 mg/5 mL parenteral solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral solution (group IV)
Study: 20605499
Drug: 80 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg/d soy isoflavones
Study: 20605499
Drug: 120 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg/d soy isoflavones
Study: 18653341
Drug: Intravenous theophylline
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous theophylline infusion
Study: 8950072
Drug: LDL apheresis
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDL apheresis treatment
Study: 1757613
Drug: Halobetasol propionate
Normalized name: Halobetasol Propionate
DrugBank: Ulobetasol (DB00596)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Halobetasol propionate 0.05% cream
Study: 6753643
Drug: Midazolam, 0.07
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam, 0.07 mg/kg (group M, 31 patients)
Study: 6753643
Drug: Hydroxyzine, 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyzine, 1.0 mg/kg (group H, 34 patients)
Study: 29583015
Drug: 1000 mg/day
Normalized name: RibaTab 1000 MG/day Compliance Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg/day resveratrol
Study: 24120713
Drug: 4 ×
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 × 100 μg FPNS
Study: 24120713
Drug: 1 ×
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 × 400 μg FPNS
Study: 24120713
Drug: 2 ×
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 × 100 μg FPNS
Study: 24120713
Drug: 4 ×
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 × 100 μg FPNS and 1 × 400 μg FPNS
Study: 21283921
Drug: Imiquimod 3.75%
Normalized name: IMIQUIMOD 3.75% CREAM,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imiquimod 3.75% cream (two-week cycle)
Study: 21283921
Drug: Imiquimod 2.5%
Normalized name: IMIQUIMOD 2.5% CREAM,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imiquimod 2.5% cream (two-week cycle)
Study: 21283921
Drug: Imiquimod 3.75%
Normalized name: IMIQUIMOD 3.75% CREAM,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imiquimod 3.75% cream (three-week cycle)
Study: 21283921
Drug: Imiquimod 2.5%
Normalized name: IMIQUIMOD 2.5% CREAM,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imiquimod 2.5% cream (three-week cycle)
Study: 19042940
Drug: Cranberry extract
Normalized name: CRANBERRY EXTRACT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranberry extract (500 mg)
Study: 12636956
Drug: Clindamycin vaginal
Normalized name: clindamycin Vaginal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin vaginal cream
Study: 18001442
Drug: Metronidazole vaginal
Normalized name: MetroNIDAZOLE Vaginal
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole vaginal suppositories
Study: 11581566
Drug: Exercise training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise training regimens differing in dose (kcal.wk‐1) and/or intensity (relative to peak VO2)
Study: 2340210
Drug: Verapamil (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (40 mg)
Study: 7404209
Drug: Low-dose intramuscular
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose intramuscular ketamine and hyaluronidase
Study: 31915163
Drug: Single-dose cephalosporin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose cephalosporin
Study: 19291119
Drug: Intralesional injections
Normalized name: flumethasone
DrugBank: Flumethasone (DB00663)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional injections of 75 microg of Heberprot‐P three times per week up to complete wound healing
Study: 17522570
Drug: Sildenafil (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (100 mg) followed by intravenous NTG (up to 80 microg/min)
Study: 17522570
Drug: Placebo followed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo followed by intravenous NTG (up to 160 microg/min)
Study: 11788176
Drug: Oral therapy
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral therapy (continuous conjugated equine estrogens (CEE) ‐ 0.625mg per day)
Study: 11788176
Drug: Transdermal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal therapy (patches delivering continuous 17beta‐estradiol (E2)‐‐0.05mg per day)
Study: 11788176
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (oral CEE and transdermal E2)
Study: 29151313
Drug: 10 physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 physical therapy sessions (Group 10)
Study: 29151313
Drug: 15 physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 physical therapy sessions (Group 15)
Study: 9014954
Drug: Cognitive behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavior therapy (CBT) during rehabilitation
Study: 8302446
Drug: Ventilated with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ventilated with O2 = 350 ml/min‐1 and N2O = 250 ml/min‐1, reducing N2O flow to keep FIO2 = 0.4
Study: 26980389
Drug: Nasal douches
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal douches based on high concentration (9 mg) and high-molecular-weight sodium hyaluronate (active treatment group)
Study: 26980389
Drug: Nasal saline
Normalized name: Nasal Saline
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nasal saline solution irrigation (control group)
Study: 15917152
Drug: Soy isoflavone
Normalized name: soy isoflavone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy isoflavone extract with PUFA supplement (two capsules per day for 24 weeks)
Study: 15917152
Drug: Placebo (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (two capsules per day for 12 weeks)
Study: 12650788
Drug: Bismuth-based quadruple
Normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bismuth-based quadruple therapy (OBMT) with omeprazole, bismuth biskalcitrate 140 mg, metronidazole 125 mg, and tetracycline 125 mg for 10 days.
Study: 12650788
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (OAC) with omeprazole 20 mg, amoxicillin 1 g, and clarithromycin 500 mg for 10 days.
Study: 8646868
Drug: Hydrocortisone-17-butyrate ointment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone-17-butyrate ointment, 0.1%
Study: 6373152
Drug: 1200 mg
Normalized name: aspirin 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg oxaprozin once daily
Study: 6373152
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg naproxen 3-times daily
Study: 22251483
Drug: Cytokine-based immunotherapy
Normalized name: Cytokine-based biologic agent IRX-2
DrugBank: IRX-2 (DB05643)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytokine-based immunotherapy
Study: 22251483
Drug: Topically applied
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topically applied immunomodulatory treatment
Study: 20705755
Drug: Standard induction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard induction and consolidation therapy
Study: 17620446
Drug: 30 min
Normalized name: Goddess Garden SPF 30 Mineral Sunscreen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 min exercise starting 120 min after dosing (EX120)
Study: 17620446
Drug: 30 min
Normalized name: Goddess Garden SPF 30 Mineral Sunscreen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 min exercise starting 240 min after dosing (EX240)
Study: 16332666
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (2.5 mg) plus vitamin B‐12 (500 microg)
Study: 16332666
Drug: Vitamin B‐6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin B‐6 (25 mg)
Study: 16332666
Drug: Riboflavin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Riboflavin (25 mg)
Study: 8583673
Drug: Bromazepam suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromazepam suppository
Study: 2476520
Drug: Aclatonium (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aclatonium (300 mg)
Study: 30694377
Drug: MRI through
Normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA spike protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRI through intravenous gadolinium administration (IV-Gd)
Study: 26124497
Drug: Intensified therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified therapy for MRD >0.1%
Study: 17914032
Drug: metformin (2,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: metformin (2,000 mg)
Study: 15280105
Drug: L-arginine 3
Normalized name: Natrol Men's Health L-Arginine 3,000mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine 3 g daily orally for 20 days